Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

Medicine, Hematology, Oncology +17

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · Blood · 2010 · 2K citations · Full text

Life Sciences, Hematology, Oncology +16

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

Brunangelo Falini, Cristina Mecucci, Enrico Tiacci et al. · New England Journal of Medicine · 2005 · 1.9K citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +14

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl et al. · The Lancet Oncology · 2010 · 581 citations

Medicine, Hematology, Oncology +16

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L.J. van Putten, Angèle Kelder et al. · Journal of Clinical Oncology · 2013 · 449 citations · Full text

Medicine, Hematology, Oncology +16